Navellier & Associates Inc. acquired a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 173,860 shares of the company's stock, valued at approximately $7,133,000. Navellier & Associates Inc. owned about 0.15% of Indivior at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of INDV. Wellington Management Group LLP acquired a new position in Indivior during the 2nd quarter valued at approximately $1,870,000. Handelsbanken Fonder AB bought a new position in Indivior in the 2nd quarter worth about $1,859,000. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Indivior in the second quarter valued at approximately $14,781,000. MRA Advisory Group bought a new stake in shares of Indivior during the second quarter valued at approximately $434,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Indivior during the second quarter valued at approximately $63,224,000. Institutional investors own 60.33% of the company's stock.
Indivior Trading Down 1.2%
Shares of NASDAQ:INDV opened at $34.87 on Friday. The company has a 50 day moving average of $39.33 and a 200-day moving average of $36.00. The firm has a market cap of $4.12 billion, a P/E ratio of 12.50 and a beta of 0.86. Indivior PLC has a twelve month low of $22.22 and a twelve month high of $42.81.
Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The business had revenue of $343.00 million for the quarter. Equities research analysts forecast that Indivior PLC will post 3.66 EPS for the current year.
Insider Buying and Selling at Indivior
In other news, insider Christian Heidbreder sold 18,586 shares of the business's stock in a transaction on Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the sale, the insider owned 209,337 shares of the company's stock, valued at approximately $8,612,124.18. The trade was a 8.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson acquired 1,500 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was purchased at an average price of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares of the company's stock, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.74% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. Zacks Research lowered Indivior from a "strong-buy" rating to a "hold" rating in a report on Monday, June 29th. Weiss Ratings downgraded Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, August 21st. Barclays reduced their price target on Indivior from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, August 5th. Finally, Craig Hallum reissued a "buy" rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat, Indivior presently has a consensus rating of "Moderate Buy" and an average target price of $45.17.
Read Our Latest Stock Report on INDV
Indivior Profile
(
Free Report)
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Featured Stories
Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
